HitGen (688222) Stock Overview
Operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
688222 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HitGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥23.23 |
| 52 Week High | CN¥30.28 |
| 52 Week Low | CN¥11.13 |
| Beta | 0.23 |
| 1 Month Change | -5.84% |
| 3 Month Change | 3.15% |
| 1 Year Change | 72.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688222 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -7.9% | -1.6% | 0.3% |
| 1Y | 72.7% | 38.8% | 17.2% |
Return vs Industry: 688222 exceeded the CN Life Sciences industry which returned 38.8% over the past year.
Return vs Market: 688222 exceeded the CN Market which returned 17.2% over the past year.
Price Volatility
| 688222 volatility | |
|---|---|
| 688222 Average Weekly Movement | 7.8% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688222's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688222's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 492 | Li Jin | www.hitgen.com |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; and HGP1069, a ROCK2 inhibitor eye drop.
HitGen Inc. Fundamentals Summary
| 688222 fundamental statistics | |
|---|---|
| Market cap | CN¥9.28b |
| Earnings (TTM) | CN¥114.11m |
| Revenue (TTM) | CN¥498.51m |
Is 688222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688222 income statement (TTM) | |
|---|---|
| Revenue | CN¥498.51m |
| Cost of Revenue | CN¥221.40m |
| Gross Profit | CN¥277.11m |
| Other Expenses | CN¥163.01m |
| Earnings | CN¥114.11m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 55.59% |
| Net Profit Margin | 22.89% |
| Debt/Equity Ratio | 17.3% |
How did 688222 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 17:49 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HitGen Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Xibing Chen | Guosen Securities Co., Ltd. |
| Ban Wang | Minsheng Securities Co. |